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Introduction {#s1}
============

Leptospirosis is a serious worldwide zoonotic disease that affects various domestic animals, including dogs [@pone.0111367-Palaniappan1], [@pone.0111367-Levett1], [@pone.0111367-Sykes1]. Leptospires are transmitted directly or indirectly, mainly through contact with infected urine, and enter the body through mucous membranes or skin abrasions [@pone.0111367-Palaniappan1], [@pone.0111367-Levett1], [@pone.0111367-Phraisuwan1]. Heavy rainfall and flooding are associated risk factors for leptospiral infection [@pone.0111367-Levett1], [@pone.0111367-Bharti1], [@pone.0111367-Cann1]. The clinical signs of leptospiral infection in dogs vary from subclinical to minimal clinical disease with mild fever to severe kidney and liver failure and pulmonary hemorrhage [@pone.0111367-Sykes1], [@pone.0111367-Klopfleisch1], [@pone.0111367-Greenlee1], [@pone.0111367-Greenlee2]. Gautam et al reported that 2,680 samples were seropositive for antibodies against *Leptospira* serovars among 33,119 canine serum samples submitted to a commercial veterinary diagnostic laboratory from 2000 through 2007 in the United States [@pone.0111367-Gautam1].

Dogs serve either as accidental hosts for various pathogenic serovars, such as serovars Grippotyphosa and Pomona, or as maintenance hosts for serovar Canicola [@pone.0111367-Palaniappan1], [@pone.0111367-Birnbaum1], [@pone.0111367-Hennebelle1], [@pone.0111367-Tangeman1]. In accidental infections with serovars Icterohaemorrhagiae and Grippotyphosa, dogs may show acute or subacute hepatic and renal failure, respectively [@pone.0111367-Greenlee1], [@pone.0111367-Tangeman1]. However, the distribution of serovars may vary between different countries; therefore different serovars were used to develop a bacterin in different areas. In Europe, four serovars, Canicola, Icterohaemorrhagiae, Grippotyphosa, and Australis have been used to develop a bacterin [@pone.0111367-Klaasen1], whereas in the USA, serovars Canicola, Icterohaemorrhagiae, Grippotyphosa, and Pomona were used for bacterin development [@pone.0111367-Midence1]. In Germany, serovars Australis, Grippotyphosa and Pomona are the predominant serogroups associated with canine leptospirosis [@pone.0111367-MayerScholl1]. In Thailand, serovar Autumnalis was the predominant serovar in an outbreak of human leptospirosis [@pone.0111367-Thaipadungpanit1], [@pone.0111367-Thaipadungpanit2]. The widespread use of bivalent vaccines containing these serovars and the increased contact between dogs and wildlife reservoirs in expanding suburban environments are likely to result in changes of the prevalent *Leptospira* serovars or the emergence of new serovars in the USA and Europe [@pone.0111367-Gautam1], [@pone.0111367-Ellis1], [@pone.0111367-Gautam2], [@pone.0111367-Stokes1]. Although dogs have been diagnosed with *Leptospira* spp infection by serology, the pathogens have not been isolated from most of these clinical cases [@pone.0111367-Sykes1], [@pone.0111367-Suepaul1]. Because of the non-specific clinical signs and variable changes in clinical pathology findings, depending on the stage of infection, multiple methods are usually employed for the diagnosis of canine leptospirosis. Four outer membrane antigens were previously found useful for the serodiagnosis of equine leptospirosis by ELISA [@pone.0111367-Ye1]. In an attempt to improve the specificity and sensitivity of the indirect ELISA test for diagnosis of canine leptospirosis, we evaluated 4 recombinant antigens (LipL21, Loa22, LipL32 and LigACon4-8). LipL21 is a surface-exposed lipoprotein [@pone.0111367-Cullen1]. Loa22 encodes a lipoprotein with an OmpA domain and it is up-regulated during host infection [@pone.0111367-Ristow1]. LipL32 makes up more than 50% of both the outer membrane subproteome and surfaceome [@pone.0111367-Pinne1]. The Lig proteins, which include LigA, LigB, and LigC, are major components of the leptospiral surface and are also upregulated during infection [@pone.0111367-Lin1], [@pone.0111367-Palaniappan2]

Materials and Methods {#s2}
=====================

Sera {#s2a}
----

Canine sera were collected from 2009 to 2012 by the New York State Animal Health Diagnostic Center (AHDC), Cornell University, Ithaca, NY. These serum samples were either positive (n = 203) or negative (n = 102) in the MAT to the following serovars: *L. interrogans* serovar Pomona, *L. kirschneri* serovar Grippotyphosa, *L. interrogans* serovar Icterohaemorrhagiae, *L. interrogans* serovar Canicola or *L. borgpetersenii* serovar Hardjo. Experiments were conducted according to the protocol approved by IACUC (Institutional Animal Care and Use Committee) at Cornell University.

MAT {#s2b}
---

MAT was used as the reference method to determine the serum titers using live *L. interrogans* as antigen as previously described [@pone.0111367-Fraune1]. Briefly, serial twofold dilutions of the sera, starting with a dilution of 1: 10, were mixed with an equal volume of viable *Leptospira* strains in a 96 well microtiter plate. After incubation at 30°C for 2 h, the samples were examined for agglutination by dark field microscopy. Titers represent the highest serum dilution showing 50% agglutination of the leptospiral cells in the suspension. MAT titers ≥1∶200 were considered a positive serum sample.

Cloning, expression, and purification of the four recombinant proteins {#s2c}
----------------------------------------------------------------------

The 4 recombinant proteins were purified as previously described [@pone.0111367-Ye1], [@pone.0111367-Yan1]. *pLip32L* was cloned into pGEX4T2(GE, USA) and expressed and purified as a GST tagged protein. The GST tag was cut with thrombin (20 U/ml in phosphate buffered saline (PBS), pH 7.3) while the fusion protein was bound to the column by incubating at room temperature for 12 h. LipL21, LigACon4-8 and Loa22 were cloned into pET28 (Invitrogen, USA), expressed and purified as His-sumo-tagged fusion proteins. His-sumo tagged proteins were digested overnight on a Ni-NTA column with sumo-specific protease Ulp-1 at 4°C. Following incubation, the untagged proteins were eluted while the GST and His-sumo tags were retained on the glutathione and Ni-NTA resin respectively. The concentrated, untagged proteins were then subjected to SDS-PAGE to check for purity and stored in -80°C until use.

Optimization of antigen concentration in ELISA assay {#s2d}
----------------------------------------------------

For each antigen, 25, 50, 100, and 200 ng of protein were coated onto different wells and incubated at 4°C overnight. A two fold serial dilution of the test sera was used at 1∶500, 1∶1,000, 1∶2,000, and 1∶4,000. The canine MAT positive and negative sera were employed as positive and negative reaction controls, respectively. A serum titer of 1∶800 was selected as the optimum dilution, based on its OD~630~ in the range 0--1.0. For rLipL21, rLipL32and rLoa22, a protein concentration of 100 ng/well was selected for performing the assay, while 50 ng/well was selected for rligA4-8 protein. These concentrations were selected on the basis of titration for optimum reactivity.

Enzyme-linked immunosorbent assay (ELISA) {#s2e}
-----------------------------------------

Indirect ELISA was performed as previously described [@pone.0111367-Ye1], [@pone.0111367-Yan1] using purified proteins of rLigACon4-8, rLipL32, rLoa22 and rLipL21. Purified proteins were diluted in coating buffer (0.05 M NaHCO~3~/Na~2~CO~3~ buffer, pH 9.6) at optimum concentration established by checkerboard titration. One hundred microliters of the diluted antigen were coated on 96-well microtiter plates (Corning, NY) and incubated at 4°C overnight and then followed by blocking with 1% bovine serum albumin in PBS. Sera were optimally diluted in PBS containing 1% bovine serum albumin and 0.05% Tween 20 and then added to the wells for 1 hour at 37°C. The IgG reactivity was detected with peroxidase-labeled anti-dog IgG (KPL, Inc. ML) and TMB 2-Component microwell peroxidase substrate (KPL, Inc. ML). The plates were read at OD~450~ on a microtiter plate reader (BioTek, VT) after the addition of the same volume of TMB stop solution (KPL, Inc. MD.

Western blot analysis {#s2f}
---------------------

Western blot analysis was performed on all canine serum samples as previously described [@pone.0111367-Ye1], [@pone.0111367-Yan1] using purified antigens, rLigACon4-8, rLipL32, rLoa22 and rLipL21. Briefly, after the purified recombinant proteins were transferred from the SDS-PAGE separation gel to a nitrocellulose membrane (Schleicher & Schuell Biosciences Inc., New Hampshire), the membranes were blocked and subjected to assay using a 1∶200 dilution of canine test serum as the primary antibody and l: 2,000 dilution of alkaline phosphatase labeled goat anti-dog IgG (KPL, ML, USA) as the secondary antibody. A serum sample that was both MAT and ELISA negative was used as the negative control and an experimental positive serum was used as a positive control.

Statistical analysis {#s2g}
--------------------

The ELISA performance was evaluated using the MAT as the reference method (gold standard) [@pone.0111367-Ye1], [@pone.0111367-Yan1]. The relative sensitivity, specificity and accuracy of ELISA for the detection of anti-*Leptospira* antibodies in dog sera were determined in comparison to the MAT as follows; Sensitivity  = a/(a+b) ×100; Specificity  = d/(c+d) ×100; Accuracy  =  \[(a + d)/(a+b+c+d)) ×100, where a is the number of samples positive by both ELISA and MAT; b is the number of samples positive by MAT but negative by ELISA; c is the number of samples negative by MAT but positive by ELISA; and d is the number of samples negative by both MAT and ELISA [@pone.0111367-Chalayon1].

Results {#s3}
=======

Evaluation of ELISA in comparison with MAT and Western blot analysis {#s3a}
--------------------------------------------------------------------

For rLipL21, rLipL32and rLoa22, a protein concentration of 100 ng/well was selected for performing the assay, while 50 ng/well was selected for rLigACon4-8 protein. These concentrations were selected on the basis of titration for optimum reactivity. Recombinant proteins rLigACon 4--8, rLipL21, rLipL32 and rLoa22 reacted with MAT positive canine serum samples, and the results are shown in [Fig. 1. A, B, C, and D](#pone-0111367-g001){ref-type="fig"} and [Table 1](#pone-0111367-t001){ref-type="table"}. The sensitivity and specificity of ELISA were 97.5% and 84.3% for rLigACon4-8; 89.7% and 81.4% for rLoa22; 92.6% and 84.3% for rLipL32 and 99.5% and 84.3% for rLipL21, respectively compared to MAT ([Table 2](#pone-0111367-t002){ref-type="table"}). When two to four proteins were used and all proteins in each group were ELISA positive, the sensitivity and specificity of ELISA are shown in [Table 3](#pone-0111367-t003){ref-type="table"}., the sensitivity and specificity of ELISA when only one of these proteins was ELISA positive is shown in [Table 4](#pone-0111367-t004){ref-type="table"}. The Western blot analysis of MAT positive and negative samples is shown in [Fig. 2](#pone-0111367-g002){ref-type="fig"}. Among MAT negative serum samples, 16, 19, 16 and 16 were ELISA positive to rLipL21, rLoa22, rLipL32 and rLigACon4-8, respectively ([Table 5](#pone-0111367-t005){ref-type="table"}). Among the MAT positive serum samples, 1, 21, 15 and 5 were ELISA negative, but 1, 15, 12, and 3 were Western blot analysis negative to LipL21, LoaL22, LipL32 and LigACon4-8 ([Table 5](#pone-0111367-t005){ref-type="table"}). The ELISA and Western blot analysis of the 29 samples that were MAT negative, but ELISA positive to at least one of these antigens is shown in [Table 6](#pone-0111367-t006){ref-type="table"}. The ELISA and Western blot analysis of the 22 samples that were MAT positive, but ELISA negative to at least one of these antigens is shown in [Table 7](#pone-0111367-t007){ref-type="table"}.

![Graph of the ELISA samples showing the IgG ELISA reactivity of 305 canine sera.\
The *x* axis indicates the MAT titers of the tested sera. The *y* axis indicates the ELISA reading at OD450. A. LipL21; B. Loa22; C, LipL32; D, LigACon4-8.](pone.0111367.g001){#pone-0111367-g001}

![Western blot analysis of canine serum.\
Sera that were MAT negative but ELISA positive (A) and MAT positive, but ELISA negative (B) were further tested by Western blotting. Purified recombinant proteins rLipL21, rLoa22, rLipL32 and rLigACon4-8 of *L. interrogans* were transferred from the SDS-PAGE separation gel to a nitrocellulose membrane. After washing with TBS, the membranes were blocked and then subjected to assay using the serum to be tested as the primary antibody and l∶3,000-diluted, alkaline phosphatase-labeled goat anti-dog IgG (KPL, Inc., MD) as the secondary antibody. After this, the membranes were incubated in freshly prepared BCIP-NBT color development solution (Invitrogen) for 10 to 30 min to see the [results](#s3){ref-type="sec"}. The number is the dog serum number that was ELISA positive.](pone.0111367.g002){#pone-0111367-g002}

10.1371/journal.pone.0111367.t001

###### MAT, ELISA and Western blot analysis of the serum sample used in this study.

![](pone.0111367.t001){#pone-0111367-t001-1}

  protein name    MAT-   MAT+                   
  -------------- ------ ------ ---- ----- ----- -----
  rLipL21         102     86    80   203   202   168
  rLoa22          102     83    59   203   182   127
  rLipL32         102     86    70   203   188   146
  rLigACon4-8     102     86    68   203   198   130

10.1371/journal.pone.0111367.t002

###### Sensitivity and specificity of the ELISA test when a single protein was evaluated in comparison to the MAT result.

![](pone.0111367.t002){#pone-0111367-t002-2}

                 sensitivity   specificity
  ------------- ------------- -------------
  rLipL21           99.5%         84.3%
  rLoa22            89.7%         81.4%
  rLipL32           92.6%         84.3%
  rLigACon4-8       97.5%         84.3%

10.1371/journal.pone.0111367.t003

###### Sensitivity and specificity of the ELISA test.

![](pone.0111367.t003){#pone-0111367-t003-3}

  proteins            a[\*](#nt102){ref-type="table-fn"}   b[\*](#nt102){ref-type="table-fn"}   c[\*](#nt102){ref-type="table-fn"}   d[\*](#nt102){ref-type="table-fn"}   Sensitivity[\#](#nt103){ref-type="table-fn"}   Specificity[\#](#nt103){ref-type="table-fn"}
  ------------------ ------------------------------------ ------------------------------------ ------------------------------------ ------------------------------------ ---------------------------------------------- ----------------------------------------------
  L21&L22                            182                                   21                                   13                                   89                                      89.7%                                          87.3%
  L21&L32                            188                                   15                                   9                                    93                                      92.6%                                          91.2%
  L21&LigA                           198                                   5                                    16                                   86                                      97.5%                                          84.3%
  L22&L32                            181                                   22                                   6                                    96                                      89.2%                                          94.1%
  L22&LigA                           182                                   21                                   13                                   89                                      89.7%                                          87.3%
  L32&LigA                           188                                   15                                   9                                    93                                      92.6%                                          91.2%
  L21&L22&L32                        181                                   22                                   6                                    96                                      89.2%                                          94.1%
  L21&L22&LigA                       182                                   21                                   13                                   89                                      89.7%                                          87.3%
  L21&L32&LigA                       188                                   15                                   9                                    93                                      92.6%                                          91.2%
  L22&L32&LigA                       181                                   22                                   6                                    96                                      89.2%                                          94.1%
  L21&L22&L32&LigA                   181                                   22                                   6                                    96                                      89.2%                                          94.1%

When all two, three or four of these recombinant proteins were tested positive, the serum sample was judged to be positive. Otherwise, it was judged to be negative.

\*a: MAT+&ELISA+; b: MAT+&ELISA-; c: MAT-&ELISA+; d:MAT-&ELISA-;

Sensitivity  = a/(a+b); specificity  = d/(c+d).

10.1371/journal.pone.0111367.t004

###### Sensitivity and specificity of the ELISA test.

![](pone.0111367.t004){#pone-0111367-t004-4}

  proteins            a[\*](#nt105){ref-type="table-fn"}   b[\*](#nt105){ref-type="table-fn"}   c[\*](#nt105){ref-type="table-fn"}   d[\*](#nt105){ref-type="table-fn"}   Sensitivity[\#](#nt106){ref-type="table-fn"}   Specificity[\#](#nt106){ref-type="table-fn"}
  ------------------ ------------------------------------ ------------------------------------ ------------------------------------ ------------------------------------ ---------------------------------------------- ----------------------------------------------
  L21&L22                            202                                   1                                    22                                   80                                      99.5%                                          78.4%
  L21&L32                            202                                   1                                    23                                   79                                      99.5%                                          77.5%
  L21&LigA                           202                                   1                                    16                                   86                                      99.5%                                          84.3%
  L22&L32                            189                                   14                                   29                                   73                                      93.1%                                          71.6%
  L22&LigA                           198                                   5                                    22                                   80                                      97.5%                                          78.4%
  L32&LigA                           198                                   5                                    23                                   79                                      97.5%                                          77.5%
  L21&L22&L32                        202                                   1                                    29                                   73                                      99.5%                                          71.6%
  L21&L22&LigA                       202                                   1                                    22                                   80                                      99.5%                                          78.4%
  L21&L32&LigA                       202                                   1                                    23                                   79                                      99.5%                                          77.5%
  L22&L32&LigA                       198                                   5                                    29                                   73                                      97.5%                                          71.6%
  L21&L22&L32&LigA                   202                                   1                                    29                                   73                                      99.5%                                          71.6%

When one of the two, three or four proteins was positive in the ELISA test in comparison to the MAT test, the serum was considered positive.

\*a: MAT+&ELISA+; b: MAT+&ELISA-; c: MAT-&ELISA+; d:MAT-&ELISA-;

Sensitivity  = a/(a+b); specificity  = d/(c+d).

10.1371/journal.pone.0111367.t005

###### Comparison of MAT negative and ELISA and Western blot analysis positive or MAT positive, but ELISA and Western blot analysis negative.

![](pone.0111367.t005){#pone-0111367-t005-5}

                 MAT-   MAT+       
  ------------- ------ ------ ---- ----
  rLipL21         16     13    1    1
  rLoa22          19     14    21   15
  rLipL32         16     12    15   12
  rLigACon4-8     16     12    5    3

10.1371/journal.pone.0111367.t006

###### The ELISA and Western blot analysis of the 29 samples that were MAT negative, but ELISA positive to one to four of these antigens.

![](pone.0111367.t006){#pone-0111367-t006-6}

  Serum \#    Lip21L[\*](#nt107){ref-type="table-fn"}   Loa22L[\*](#nt107){ref-type="table-fn"}   Lip32L[\*](#nt107){ref-type="table-fn"}   LipACon4-8[\*](#nt107){ref-type="table-fn"}
  ---------- ----------------------------------------- ----------------------------------------- ----------------------------------------- ---------------------------------------------
  1                             +/+                                       −/+                                       +/+                                         +/+
  2                             +/+                                       −/+                                       +/+                                         +/+
  3                             −/−                                       −/−                                       +/+                                         −/−
  4                             −/−                                       −/−                                       +/−                                         −/−
  5                             −/−                                       −/−                                       +/−                                         −/−
  6                             −/−                                       −/−                                       +/+                                         −/−
  7                             −/−                                       −/−                                       +/+                                         −/−
  8                             −/−                                       −/−                                       +/−                                         −/−
  9                             −/−                                       −/−                                       +/−                                         −/−
  10                            −/−                                       +/+                                       −/−                                         −/−
  11                            +/+                                       +/+                                       −/−                                         +/+
  12                            +/−                                       +/+                                       −/−                                         +/−
  13                            +/+                                       +/+                                       −/−                                         +/−
  14                            +/+                                       +/+                                       −/−                                         +/+
  15                            +/−                                       +/−                                       −/−                                         +/−
  16                            +/+                                       +/+                                       −/−                                         +/+
  17                            −/−                                       +/−                                       −/−                                         −/−
  18                            +/−                                       +/+                                       −/−                                         +/−
  19                            +/+                                       +/+                                       +/+                                         +/+
  20                            +/+                                       +/+                                       +/+                                         +/+
  21                            +/+                                       +/+                                       +/+                                         +/+
  22                            +/+                                       +/+                                       +/+                                         +/+
  23                            +/+                                       +/+                                       +/+                                         +/+
  24                            +/+                                       +/+                                       +/+                                         +/+
  25                            −/−                                       +/−                                       −/−                                         −/−
  26                            −/−                                       +/+                                       −/−                                         −/−
  27                            −/−                                       +/−                                       −/−                                         −/−
  28                            +/+                                       −/−                                       +/+                                         +/+
  29                            −/−                                       +/−                                       −/−                                         −/−

\* ELISA/WB: -, negative; + is positive.

10.1371/journal.pone.0111367.t007

###### The ELISA and Western blot analysis of the 22 samples that were MAT positive, but ELISA negative to at least one to four of these antigens.

![](pone.0111367.t007){#pone-0111367-t007-7}

  Serum \#    Lip21L[\*](#nt108){ref-type="table-fn"}   Loa22L[\*](#nt108){ref-type="table-fn"}   Lip32L[\*](#nt108){ref-type="table-fn"}   LipACon4-8[\*](#nt108){ref-type="table-fn"}
  ---------- ----------------------------------------- ----------------------------------------- ----------------------------------------- ---------------------------------------------
  1                             +/+                                       −/−                                       −/−                                         +/+
  2                             +/+                                       −/+                                       +/+                                         +/+
  3                             −/−                                       −/−                                       −/−                                         −/−
  4                             +/−                                       −/−                                       −/−                                         +/−
  5                             +/−                                       −/−                                       −/−                                         +/−
  6                             +/−                                       −/−                                       −/−                                         +/−
  7                             +/+                                       −/+                                       +/+                                         +/+
  8                             +/−                                       −/−                                       −/−                                         −/+
  9                             +/−                                       −/−                                       −/−                                         +/+
  10                            +/−                                       −/−                                       −/−                                         +/−
  11                            +/+                                       −/−                                       +/+                                         +/+
  12                            +/+                                       −/−                                       −/+                                         +/+
  13                            +/+                                       −/−                                       −/−                                         +/−
  14                            +/+                                       −/+                                       +/+                                         +/+
  15                            +/+                                       +/+                                       −/+                                         +/+
  16                            +/+                                       −/−                                       −/−                                         −/−
  17                            +/+                                       −/−                                       −/−                                         −/+
  18                            +/+                                       −/−                                       +/+                                         +/+
  19                            +/+                                       −/−                                       −/−                                         −/−
  20                            +/+                                       −/+                                       −/+                                         +/+
  21                            +/+                                       −/+                                       +/+                                         +/+
  22                            +/+                                       −/+                                       +/+                                         +/+

\* ELISA/WB: -, negative; + is positive.

Discussion {#s4}
==========

The diagnosis of canine Leptospirosis is usually based on direct observation of leptospires in blood or urine samples, the isolation of the pathogens in culture, seropositivity for *Leptospira*-specific antibodies, and/or the demonstration of *Leptospira* DNA by PCR-based assays [@pone.0111367-Palaniappan3]. The use of these diagnostic techniques for the diagnosis of leptospirosis in dogs has been previously reported [@pone.0111367-Schreier1]. The standard method for diagnosis of leptospirosis is the microscopic agglutination test (MAT), in which serum samples are reacted with live antigen suspensions of *Leptospira* serovars. However, MAT is laborious, time consuming and requires maintaining cultures of the various serovars that are prevalent in some regions but not in others. Thus, considerable efforts are being made to develop novel, sensitive, and specific diagnostic tests for leptospirosis that are less labor and resource intensive. The performance of MAT is restricted only to the laboratories that can maintain strains for the preparation of live antigens. To culture the organism from tissues or body fluids, it is very important to know the stage of infection of the animals; *Leptospira* can only be cultured from blood samples in the acute phase which usually lasts for about 10 days. After the antibody response is detected (at approximately 10 days), *Leptospira* are cleared from the blood. During the second phase, which may last up to several months, bacteriuria is often intermittent, which makes the culture results inconsistent. For the same reason the molecular diagnossis of leptospirosis is only suitable in the early and convalescent stages of infection, although it has been shown to be sensitive and specific. Hence, currently most cases of leptospirosis are still diagnosed by serology. In infected animals, antibodies become detectable by the 6th to 10th day of disease and reach peak levels within three to four weeks. The antibody levels then gradually decline but still can be detected for years [@pone.0111367-Budihal1]. Thus, considerable efforts are being made to develop novel, sensitive, and specific serological diagnostic tests for leptospirosis that are less labor and resource intensive. Enzyme linked immunosorbent assay (ELISA) methods are a potential diagnostic tool for the serodiagnosis of leptospirosis [@pone.0111367-Yan1], [@pone.0111367-Chen1], [@pone.0111367-Bourhy1]. Attempts have been made to develop either an ELISA serodiagnostic test [@pone.0111367-Chalayon1], [@pone.0111367-Bomfim1], [@pone.0111367-Flannery1], [@pone.0111367-Croda1], [@pone.0111367-Hartleben1], [@pone.0111367-Joseph1], [@pone.0111367-Oliveira1], [@pone.0111367-Sankar1], [@pone.0111367-Srimanote1] or a Dual Path Platform (DPP) assay, a point-of-care immunoassay [@pone.0111367-Nabity1]. We previously used the LigA protein for diagnosis of equine and canine leptospirosis [@pone.0111367-Ye1], [@pone.0111367-Yan1], [@pone.0111367-Palaniappan3], [@pone.0111367-Donskey1] and rLigACon4-8, rLipL32, rLoa22 and rLipL21 for diagnosis of equine leptospirosis [@pone.0111367-Ye1]. We hypothesized that the use of these four antigens in the ELISA test would improve the sensitivity and specificity of this serologic test to canine leptospirosis.

We collected 203 positive plus 102 negative MAT canine sera from 2010 to 2012, for further ELISA evaluation using the four test antigens. The MAT test targets both IgM and IgG, but is skewed towards IgG [@pone.0111367-Palaniappan1], [@pone.0111367-Faine1]. Because most of the canine serum samples did not come from an early leptospiral infection, we used rLigConA4-8, rLipL32, rLipL21 and rLoa22 proteins as the coated antigen to establish an ELISA for improved detection of specific IgG in sera from canine patients with positive titers in the MAT test.

A four-fold rise in titer or seroconversion has been used as the definitive criterion for the serologic diagnosis of active leptospirosis. This requires collecting serum samples from the same animal 3 or 4 weeks later and this delay is not practical in the clinical setting. Alternatively, a single high MAT titer may be taken as evidence of active infection. Therefore, the WHO Leptospirosis Burden Epidemiology Reference Group (LERG) and the Centers for Disease Control and Prevention (CDC), US have recently defined a MAT titer of 400 in a single serum specimen as evidence supporting laboratory confirmation [@pone.0111367-Group1], [@pone.0111367-Public1]. A defined positive titer is also needed in dogs. Cautam, et al. selected ≥1∶1,600 as positive [@pone.0111367-Gautam1]. A MAT ≤400 is not considered indicative of disease attributable to leptospirosis [@pone.0111367-Raghavan1]. In Switzerland, a MAT titer ≥800 is defined as positive for clinical canine leptospirosis [@pone.0111367-Barmettler1]. However, Andre-Fontaine sets a MAT titer \<320 as the cutoff for non-infected, vaccinated dogs [@pone.0111367-AndreFontaine1]. Therefore, further studies are needed to select a universal cut off for the serodiagnosis of canine leptospirosis.

Interestingly, we found that 16, 19, 16, and 16 MAT negative serum samples were positive by ELISA when using rLipL21, rLoa22, rLipL32 and rLigACon4-8 as antigens, respectively. This is not surprising since some of these antigens may be not expressed well by leptospires grown in vitro and MAT would not be able to detect antibody in these serum samples [@pone.0111367-Palaniappan2], [@pone.0111367-Haake1], [@pone.0111367-Matsunaga1]. We further evaluated these MAT negative/ELISA positive serum samples by Western blot analysis, and found that 13/16, 14/19, 12/16 and 12/16 of these respective samples were Western blot analysis positive. This suggests that these dogs were either infected or vaccinated previously but the MAT antibody titers to *Leptospira* lipopolysaccharide antigens declined below the detection threshold (\<1∶200). Similarly, some urine culture positive dogs are MAT negative [@pone.0111367-vanDenBroek1]. We did not have animal histories that would have allowed us to ascertain the *Leptospira* vaccination status of the dogs and/or if they exhibited any clinical signs of leptospirosis.

We also found that 1, 21, 15, and 5 MAT positive serum samples were negative by ELISA when using rLipL21, rLoa22, rLipL32 and rLigACon4-8 as antigens, respectively. However, Western blot analysis indicated only one of these ELISA negative samples was negative to all four recombinant antigens while the rest were positive to at least one of these antigens ([Table 7](#pone-0111367-t007){ref-type="table"}).

In conclusion, the ELISA developed utilizing rLipL21, rLoa22, rLipL32 and rLigACon4-8 as antigens could increase the sensitivity and specificity of the ELISA test to detect leptospirosis in dogs. This ELISA test may be able to replace or supplement the current canine MAT test for the diagnosis of canine leptospirosis in the near future after further validation with more defined canine serum samples from known infected and vaccinated dogs.
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